Changes/additions to materials (reviewed 20/07/10):

NICE has published the final appraisal determination (FAD) regarding drugs for the treatment of rheumatoid arthritis after failure of a TNF inhibitor. A FAD is also available for tocilizumab for rheumatoid arthritis. Please note that these are not final guidance, which is expected to be published in August 2010.

NICE has published guidance (TA186) recommending certolizumab pegol▼ as an option for the treatment of adults with rheumatoid arthritis (RA) only if:

• the drug is used in the same way as defined in the NICE TA130  for adalimumab▼, etanercept▼ and infliximab, and
• the manufacturer provides the first 12 weeks of certolizumab pegol▼ free of charge to all patients starting treatment.

More information is contained in the NPCi blog.

Test your knowledge (or just have some fun) by answering the questions in this quiz. Suggested answers are given after each question with some additional information and references. You even get a score at the end that you can print out and put in your CPD folder!

To reveal the answer to the quiz questions click on the arrow button at the bottom. The answer will then appear, however, you may need to use the slider on the right hand side of the page to reveal the whole text.

Date of last update March 2010